AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22230187 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched with EI therapy group)
Number of subjects: 128
Study 20048543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraflexible training shoe (Nike Free 5.0)
Number of subjects: 21
Study 20048543 — intervention group
Group type: COMPARATOR
Intervention: Conventional training shoe
Number of subjects: 21
Study 17263896 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-centered dietary modification program
Number of subjects: 0
Study 17263896 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-centered physical activity skill-development program
Number of subjects: 0
Study 17263896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program of dietary modification and physical activity skill-development
Number of subjects: 0
Study 15802109 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement of blood pressure (SMBP) using OMRON HEM‐705CP automatic blood pressure monitor for 15 days at weeks 6 and 14.
Number of subjects: 1325
Study 15802109 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control group).
Number of subjects: 1325
Study 11169930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg per day
Number of subjects: 769
Study 11169930 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 40 mg four times daily
Number of subjects: 769
Study 10209938 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion (20 g over 2 hours)
Number of subjects: 24
Study 10209938 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels of nitrites, endothelin, and E-selectin
Number of subjects: 24
Study 7933426 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine resin (placebo-controlled)
Number of subjects: 1899
Study 3252755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg single oral dose
Number of subjects: 45
Study 3252755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30218514 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature Infant Oral Motor Intervention (structured stimulation)
Number of subjects: 30
Study 30218514 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (unstructured stimulation)
Number of subjects: 30
Study 29507779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) with 100 mg aspirin daily
Number of subjects: 348
Study 29507779 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aspirin daily (Control)
Number of subjects: 348
Study 26241263 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR reminder for type 2 diabetes screening
Number of subjects: 847
Study 26241263 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 847
Study 23591306 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 60
Study 23591306 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 60
Study 23591306 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel and Endotracheal intubation
Number of subjects: 60
Study 21072235 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose rifampicin (SDR)
Number of subjects: 21711
Study 21072235 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard multidrug therapy (MDT) program with additional chemoprophylaxis
Number of subjects: 21711
Study 21072235 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighbours of neighbours and social contacts
Number of subjects: 21711
Study 21072235 — intervention group
Group type: EXPERIMENTAL
Intervention: Next door neighbours
Number of subjects: 21711
Study 21072235 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contacts
Number of subjects: 21711
Study 21072235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21711
Study 18946448 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wave diathermy (SWD) and non-steroidal anti-inflammatory drugs (NSAID)
Number of subjects: 102
Study 18946448 — intervention group
Group type: COMPARATOR
Intervention: Placebo SWD and NSAID
Number of subjects: 102
Study 17184455 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% glacial acetic acid, 0.1% dexamethasone and 3250 U/ml of neomycin sulphate
Number of subjects: 109
Study 17184455 — intervention group
Group type: COMPARATOR
Intervention: 2% glacial acetic acid
Number of subjects: 109
Study 14740951 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV candidate vaccines
Number of subjects: 65
Study 14740951 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV-1, DENV-2, DENV-3 candidate vaccines
Number of subjects: 65
Study 14740951 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV-2, DENV-3, DENV-4 vaccine candidates
Number of subjects: 65
Study 14740951 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV-1 45AZ5 PDK 20, DENV-2 S16803 PDK 50, DENV-3 CH53489 PDK 20, DENV-4 341750 PDK 20
Number of subjects: 65
Study 10952481 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (100 mg)
Number of subjects: 20
Study 10952481 — intervention group
Group type: COMPARATOR
Intervention: Thiamine nitrate (100 mg)
Number of subjects: 20
Study 9278568 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (0.11 mmol / 60 mg)
Number of subjects: 10
Study 9278568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (0.11 mmol)
Number of subjects: 10
Study 9278568 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of beta-carotene and lycopene (0.11 mmol each)
Number of subjects: 10
Study 9278568 — intervention group
Group type: COMPARATOR
Intervention: Control (Beta-carotene alone)
Number of subjects: 10
Study 8346491 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 35
Study 8346491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (freon gas alone)
Number of subjects: 35
Study 8346491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2952151 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 641
Study 2952151 — intervention group
Group type: COMPARATOR
Intervention: Ionic monomers
Number of subjects: 641
Study 31648564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (5 mg/kg) for 4 weeks
Number of subjects: 9
Study 31648564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg/kg) for 4 weeks
Number of subjects: 9
Study 31648564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of prednisone (20 mg for 5 days)
Number of subjects: 9
Study 31648564 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing concentrations (0-200 ng/mL) of prednisone or prednisolone
Number of subjects: 9
Study 31648564 — intervention group
Group type: COMPARATOR
Intervention: GC-receptor antagonist (RU486)
Number of subjects: 9
Study 31648564 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids in fibroblasts
Number of subjects: 9
Study 29514574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical empowerment program
Number of subjects: 60
Study 29514574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 27530961 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAT Cancer
Number of subjects: 222
Study 26036965 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls Active intervention
Number of subjects: 1600
Study 26036965 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 1600
Study 23520150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH; tinzaparin)
Number of subjects: 480
Study 23520150 — intervention group
Group type: COMPARATOR
Intervention: Usual care (tinzaparin plus warfarin for ≥12 weeks at home)
Number of subjects: 480
Study 21538451 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic drug
Number of subjects: 0
Study 21538451 — intervention group
Group type: COMPARATOR
Intervention: Standard drug
Number of subjects: 0
Study 19357918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Marcaine
Number of subjects: 73
Study 19357918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 73
Study 17823445 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean isoflavones with inulin (3.66 g)
Number of subjects: 12
Study 17823445 — intervention group
Group type: COMPARATOR
Intervention: Soybean isoflavones without inulin
Number of subjects: 12
Study 15282384 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP; 250 microg twice daily) for 2 weeks
Number of subjects: 10
Study 11606172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg
Number of subjects: 7
Study 11606172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9602688 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg for 30 to 40 days (mean 35)
Number of subjects: 13
Study 9602688 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg for 21 to 50 days (mean 37)
Number of subjects: 13
Study 9602688 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1500 mg for 20 days
Number of subjects: 13
Study 9602688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose maintenance treatment with azithromycin for 30 to 360 days (mean 129)
Number of subjects: 13
Study 9602688 — intervention group
Group type: COMPARATOR
Intervention: Short term initial course of azithromycin (various doses)
Number of subjects: 13
Study 7516576 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily
Number of subjects: 100
Study 7516576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2711711 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐medicamentous therapy (CNT)
Number of subjects: 73
Study 2711711 — intervention group
Group type: COMPARATOR
Intervention: Medicamentous therapy
Number of subjects: 73
Study 14253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 12.5, 25.0, 37.5, and 50.0 mg/kg
Number of subjects: 110
Study 14253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea administered parenterally
Number of subjects: 110
Study 14253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 25.0, 37.5, and 50.0 mg/kg
Number of subjects: 110
Study 14253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea calculated by surface area
Number of subjects: 110
Study 14253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 12.5 mg/kg (low dose)
Number of subjects: 110
Study 344159 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (2 X 5 mg protamine-zinc glucagon intramuscularly per day)
Number of subjects: 69
Study 344159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 344159 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon and Placebo (total group of 69 patients)
Number of subjects: 69
Study 31924562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 9901
Study 31924562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901
Study 31348727 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board exercises combined with conventional physiotherapy
Number of subjects: 30
Study 31348727 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 30
Study 29949284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertubation treatment
Number of subjects: 42
Study 29949284 — intervention group
Group type: COMPARATOR
Intervention: Stable group (control)
Number of subjects: 42
Study 25492501 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-only colonoscopy
Number of subjects: 0
Study 25492501 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial fecal immunochemical testing
Number of subjects: 0
Study 23344921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 84
Study 23344921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 84
Study 23344921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 20833822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR)
Number of subjects: 181
Study 20833822 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 181
Study 19967596 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte solution
Number of subjects: 17
Study 19967596 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 17
Study 17218326 — intervention group
Group type: EXPERIMENTAL
Intervention: Health assessment programme
Number of subjects: 453
Study 15126989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhASB (1.0 mg/kg)
Number of subjects: 6
Study 15126989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhASB (0.2 mg/kg)
Number of subjects: 6
Study 12641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta- and gamma-based vascular brachytherapy
Number of subjects: 0
Study 12641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose around 20 Gy of brachytherapy
Number of subjects: 0
Study 12641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled dose escalation of brachytherapy
Number of subjects: 0
Study 9817690 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment (n = 11)
Number of subjects: 29
Study 9817690 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 29
Study 7656830 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 167
Study 7656830 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide
Number of subjects: 167
Study 7656830 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (Qi Lu)
Number of subjects: 167
Study 7656830 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (Qi Lu) and Zofran (Glaxo)
Number of subjects: 167
Study 2570971 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patches (2 x 100 micrograms) with norethisterone 5 mg from day 19-26 of the cycle
Number of subjects: 40
Study 2570971 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches with norethisterone 5 mg from day 19-26 of the cycle
Number of subjects: 40
Study 1233519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam, 30 mgs. daily
Number of subjects: 0
Study 1233519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1233519 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethyl-diazepam products
Number of subjects: 0
Study 30157115 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 1165
Study 30157115 — intervention group
Group type: COMPARATOR
Intervention: No oral iron supplementation (Control)
Number of subjects: 1165
Study 30157115 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation in hypertensive participants
Number of subjects: 1165
Study 30157115 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation in hypertensive participants without anemia
Number of subjects: 1165
Study 28501522 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan (75 or 100 mg/day)
Number of subjects: 2354
Study 28501522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2354
Study 28501522 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 2354
Study 28501522 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan withdrawal
Number of subjects: 2354
Study 25385685 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Transition Program (CTP)
Number of subjects: 26
Study 25385685 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinical Practice (SCP)
Number of subjects: 26
Study 24621800 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 467
Study 24621800 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 467
Study 21534496 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-optimized ablation (group I)
Number of subjects: 84
Study 21534496 — intervention group
Group type: COMPARATOR
Intervention: Topography-guided ablation (group II)
Number of subjects: 84
Study 19225269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged guided computer use with internet connection for 12 months
Number of subjects: 191
Study 19225269 — intervention group
Group type: COMPARATOR
Intervention: Training/No intervention
Number of subjects: 191
Study 19225269 — intervention group
Group type: COMPARATOR
Intervention: No training/No intervention
Number of subjects: 191
Study 19225269 — intervention group
Group type: COMPARATOR
Intervention: No interest in computer use
Number of subjects: 191
Study 16860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 2082
Study 16860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2082
Study 16860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (with/without)
Number of subjects: 2082
Study 16860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis In Myocardial Infarction grade 3 flow at baseline
Number of subjects: 2082
Study 16860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 2082
Study 16860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic target vessel revascularization
Number of subjects: 2082
Study 14500934 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated weighted average MAP
Number of subjects: 1455
Study 14500934 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% increase from baseline MAP
Number of subjects: 1455
Study 11578994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 152
Study 11578994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 9872520 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole)
Number of subjects: 109
Study 9872520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ox2AC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg b.i.d. omeprazole)
Number of subjects: 109
Study 9872520 — intervention group
Group type: EXPERIMENTAL
Intervention: OACS (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole, 100 mg t.i.d. sofalcone)
Number of subjects: 109
Study 7913155 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (50 micrograms twice daily) plus BDP
Number of subjects: 429
Study 7913155 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose BDP (500 micrograms twice daily)
Number of subjects: 429
Study 2915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years)
Number of subjects: 74
Study 2915235 — intervention group
Group type: COMPARATOR
Intervention: Standard VAC therapy for 2 years or VA for 1 year (Control)
Number of subjects: 74
Study 1104047 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg/day
Number of subjects: 24
Study 1104047 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 400 mg/day
Number of subjects: 24
Study 1104047 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg/day with bendrofluazide 5 mg/day
Number of subjects: 24
Study 1104047 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg/day
Number of subjects: 24
Study 31715553 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-ideal images
Number of subjects: 126
Study 31715553 — intervention group
Group type: COMPARATOR
Intervention: Control images (scenery)
Number of subjects: 126
Study 30035357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dorsal penile nerve block
Number of subjects: 310
Study 30035357 — intervention group
Group type: COMPARATOR
Intervention: Landmark dorsal penile nerve block
Number of subjects: 310
Study 30035357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 310
Study 26172217 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of PrEP
Number of subjects: 328
Study 26172217 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for PrEP availability outside a clinical trial
Number of subjects: 328
Study 26172217 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to supporting PrEP availability
Number of subjects: 328
Study 26172217 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient inquiries about PrEP
Number of subjects: 328
Study 26172217 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient inquiries in non-PROUD clinics
Number of subjects: 328
Study 24912464 — intervention group
Group type: EXPERIMENTAL
Intervention: Escape modeling group (parent models premature termination of hyperventilation exercise)
Number of subjects: 50
Study 24912464 — intervention group
Group type: COMPARATOR
Intervention: No escape modeling group (parent models completing hyperventilation exercise)
Number of subjects: 50
Study 21987394 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab 60 mg
Number of subjects: 16
Study 21987394 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab 200 mg
Number of subjects: 16
Study 21987394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21987394 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab (ex vivo)
Number of subjects: 16
Study 20367671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroglycolic extract of Piptadenia colubrina (HEPC) in a gel-cream formulation
Number of subjects: 0
Study 20367671 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18068618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma N-BNP
Number of subjects: 52
Study 18068618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma MMP-9
Number of subjects: 52
Study 18068618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma MMP-2
Number of subjects: 52
Study 15909264 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal therapy (mold-active antifungal drugs)
Number of subjects: 315
Study 15909264 — intervention group
Group type: COMPARATOR
Intervention: Index cutoff value of 1.5
Number of subjects: 315
Study 15909264 — intervention group
Group type: COMPARATOR
Intervention: Index cutoff value of 0.5
Number of subjects: 315